Cardiff Oncology, Inc. (CRDF)
$1.08+1.89%Close
SELLCRISIS · day 6
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $71M
- Beta
- 1.42
- P/E (TTM)
- -1.78
- Short % float
- 18.31%
- Days to cover
- 17.2
- SI change
- -1.9%
- 1W
- -3.57%
- 1M
- -10.74%
- vs SPY 1W
- -4.73%
- vs SPY 1M
- -13.74%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on CRDF?
- LOPJLB’s latest quantitative signal on Cardiff Oncology, Inc. (CRDF) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is CRDF in?
- Cardiff Oncology, Inc. (CRDF) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Cardiff Oncology, Inc. (CRDF) do?
- Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials …